A Manhattan federal judge has rejected Martin Shrkeli’s bid to escape an antitrust lawsuit seeking to ban the imprisoned executive from ever working in the pharmaceutical industry, after the price of his company’s lifesaving drug, Daraprim, suddenly spiked more than 4,000% in 2015.

U.S. District Judge Denise L. Cote of the Southern District of New York said Tuesday there was reason to believe that alleged scheme at Shkreli’s Vyera Pharmaceuticals was still occurring, more than five years after the price of the company’s branded drug increased overnight to $750 per pill.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]